RE-021 (Sparsentan)
RET-D-001
Phase 2 small_molecule completed
Quick answer
RE-021 (Sparsentan) for Focal Segmental Glomerulosclerosis is a Phase 2 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Travere Therapeutics
- Indication
- Focal Segmental Glomerulosclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed